英文药名：Epoetin Kappa([Genetical Recombination]Epoetin Alfa Biosimilar)

中文药名：重组促红细胞生成素卡帕（依泊汀生物仿制药）

生产厂家：JCR制药
一般名
エポエチン　カッパ（遺伝子組換え）［エポエチンアルファ後続1］
一般名（欧名） Epoetin Kappa（Genetical Recombination）［Epoetin Alfa Biosimilar 1］
本質
促红细胞生成素的Kappa是重组人红细胞生成素，在中国仓鼠卵巢细胞中产生。促红细胞生成素的Kappa糖蛋白，其由165个氨基酸残基（分子量：约28000）。
适应症
透析肾性贫血
早产儿贫血
用法用量
透析肾性贫血
给药初期，如阿法依伯汀（基因重组）[随后1]，通常是，成人，每周一次3000国际单位三次，以静脉内给药，以尽可能地慢。
贫血改善效果，作为维持量，通常，成人，每周一次，每周1500国际单位两次或三次，或一旦3000国际单位待施用两次。
血红蛋白浓度和周围贫血改善效果（30％血细胞比容）为10g / dL的目标值。
此外，贫血症状在任何情况下的程度，将根据年龄等调整，在维持剂量的最高剂量，一旦3000国际单位，和每周三次施用。
早产儿贫血
每周皮下注射一次，200国际单位/千克的两倍。
但是，出于对早产儿早期贫血的生活，（30％血细胞比容）为10g/dL的血红蛋白浓度中止给药，如果临床症状被认为已稳定在约。
此外，它会根据贫血症状的程度进行调节。
包装规格[促红细胞生成素阿尔法]
BS注  750“JCR”  10瓶

BS注  1500“JCR” 10瓶

BS注  3000“JCR” 10瓶

BS  750注注射器“JCR”10注射器
BS  1500注注射器“JCR”10注射器
BS  3000注注射器“JCR”10注射器

制造厂商
JCR制药有限公司

http://www.kegg.jp/medicus-bin/japic_med?japic_code=00058480
Epoetin Alfa BS Injection 1500 Syringe "JCR" [Renal Anemia in Dialysis Patients]
Brand name : Epoetin Alfa BS Injection 1500 "JCR" [Renal Anemia in Dialysis Patients]
　Active ingredient: Epoetin kappa (genetical recombination) [Epoetin alfa biosimilar 1]
　Dosage form: injection
　Print on wrapping:
-----------------------------------------------
Epoetin Alfa BS Injection 1500 Syringe "JCR" [Renal Anemia in Dialysis Patients]
Brand name : Epoetin Alfa BS Injection 1500 Syringe "JCR" [Renal Anemia in Dialysis Patients]
　Active ingredient: Epoetin kappa (genetical recombination) [Epoetin alfa biosimilar 1]
　Dosage form: injection
　Print on wrapping:
-----------------------------------------------
Epoetin Alfa BS Injection 3000 "JCR" [Renal Anemia in Dialysis Patients]
Brand name : Epoetin Alfa BS Injection 3000 "JCR" [Renal Anemia in Dialysis Patients]
　Active ingredient: Epoetin kappa (Genetical recombination) [Epoetin alfa biosimilar 1]
　Dosage form: injection
　Print on wrapping:
-----------------------------------------------
Epoetin Alfa BS Injection 3000 Syringe "JCR" [Renal Anemia in Dialysis Patients]
Brand name : Epoetin Alfa BS Injection 3000 Syringe "JCR" [Renal Anemia in Dialysis Patients]
　Active ingredient: Epoetin kappa (genetical recombination) [Epoetin alfa biosimilar 1]
　Dosage form: injection
　Print on wrapping:
-----------------------------------------------
Effects of this medicine
This medicine promotes differentiation/multiplication of red blood cells by binding to erythropoietin receptors developing mainly in erythroblastic precursor cells inside the spinal cord.
It is usually used to improve anemia in dialysis patients by increasing red blood cells.
Before using this medicine, be sure to tell your doctor and pharmacist
•If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
If you have myocardial infarction, pulmonary infarction, cerebral infarction, hypertension or allergic predisposition.
•If you are pregnant or breastfeeding.
•If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)
Dosing schedule (How to take this medicine)
•Your dosing schedule prescribed by your doctor is <<to be written by a healthcare professional>>
•In general, inject this medicine intravenously as slowly as possible 3 times a week in the early phase of treatment and 2 to 3 times a week after effects are obtained.
•This medicine may be used for a long period of time depending the effects.
•In cases where this medicine is used for the first time or after a long interval, a small amount may be injected intravenously to check for abnormalities.
Precautions while taking this medicine
•Pay close attention to manage your blood pressure since this medicine may increase blood pressure.
•This medicine may cause hyperkalemia. Follow adequate dietary control.
•You need to take iron to get an effect. If you are prescribed iron preparation, you should take it as instructed by your doctor.
Possible adverse reactions to this medicine
The most commonly reported adverse reactions include increased blood pressure, headache and rash. If any of these symptoms occurs, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
•hives, respiratory distress, lip edema [shock, anaphylactoid symptoms]
•headache, disturbance of consciousness, convulsion [hypertensive encephalopathy, cerebral bleeding]
•anginal pain, respiratory distress, sudden paralysis of one-sided limbs or face [myocardial infarction, pulmonary infarction, cerebral infarction]
•palpitation or shortness of breath when walking up stairs or a slope, headache, general malaise [pure red cell aplasia]
•yellow discoloration of the skin and the white of eyes, general malaise, loss of appetite [liver dysfunction, jaundice]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.
Storage conditions and other information